Skip to main content
. 2015 Feb 17;75(4):791–803. doi: 10.1007/s00280-015-2701-3

Table 2.

In vitro VEGF165 concentrations after addition of bevacizumab

VEGF165 standards (ng/L) VEGF165:bevacizumab molar ratio VEGF165 concentrations (ng/L)
1000 1:0 1120.2 (2.67)
1:0.1 448.5 (1.66)
1:1 452.2 (0.83)
1:1000 0 (0)
250 1:0 172.4 (4.33)
1:0.1 79.1 (4.72)
1:1 79.1 (4.72)
1:1000 0 (0)

VEGF165 concentrations are expressed as average (RSE %)